Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2
Joseph Newman, Nazia Thakur, Thomas P. Peacock, et al.
Nature Microbiology (2022) Vol. 7, Iss. 8, pp. 1180-1188
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

SARS-CoV-2 variant biology: immune escape, transmission and fitness
Alessandro M. Carabelli, Thomas P. Peacock, Lucy Thorne, et al.
Nature Reviews Microbiology (2023)
Open Access | Times Cited: 937
Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies
Yingying Hou, Min Chen, Yuan Bian, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 20
Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥ 65 years in the United States
Brenna Kirk, Christopher Bush, Astra Toyip, et al.
Vaccine (2024) Vol. 42, Iss. 25, pp. 126113-126113
Open Access | Times Cited: 7
Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature
Diego Cantoni, Craig Wilkie, Emma M. Bentley, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France
Cynthia Tamandjou, Vincent Auvigne, Sophie Vaux, et al.
Vaccine (2023) Vol. 41, Iss. 13, pp. 2280-2288
Open Access | Times Cited: 16
Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India
T. S. Selvavinayagam, Anavarathan Somasundaram, Jerard Maria Selvam, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
SARS-CoV-2 Variants: Genetic Insights, Epidemiological Tracking, and Implications for Vaccine Strategies
Fatimah S. Alhamlan, Ahmed A. Al‐Qahtani
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1263-1263
Open Access
SARS-CoV-2 seroprevalence and associated risk factors in adult outpatients from Western Romania, January to March 2023: a seroepidemiological assessment after three years of COVID-19 pandemic
Tudor Rareș Olariu, Sorin Ursoniu, Alina Cristiana Craciun, et al.
Infectious Diseases (2025), pp. 1-11
Open Access
Using minor variant genomes and machine learning to study the genome biology of SARS-CoV-2 over time
Xiaofeng Dong, David A. Matthews, Giulia Gallo, et al.
Nucleic Acids Research (2025) Vol. 53, Iss. 4
Open Access
Antibody and B Cell Responses to SARS-CoV-2 Infection and Vaccination: The End of the Beginning
Katharina Röltgen, Scott D. Boyd
Annual Review of Pathology Mechanisms of Disease (2023) Vol. 19, Iss. 1, pp. 69-97
Open Access | Times Cited: 14
Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence
Lavanya Visvabharathy, Zachary S. Orban, Igor J. Koralnik
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 19
COVID vaccination in older adults
Sara Hägg, Dorota Religa
Nature Microbiology (2022) Vol. 7, Iss. 8, pp. 1106-1107
Open Access | Times Cited: 18
COVID-19 Clinical Features and Outcomes in Elderly Patients during Six Pandemic Waves
Roxana Manuela Fericean, Ovidiu Roşca, Cosmin Cîtu, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 22, pp. 6803-6803
Open Access | Times Cited: 18
Age differentially impacts adaptive immune responses induced by adenoviral versus mRNA vaccines against COVID-19
Beatrice Dallan, Davide Proietto, Martina De Laurentis, et al.
Nature Aging (2024) Vol. 4, Iss. 8, pp. 1121-1136
Open Access | Times Cited: 3
Magnitude and Duration of Serum Neutralizing Antibody Titers Induced by a Third mRNA COVID-19 Vaccination against Omicron BA.1 in Older Individuals
Jun-Sun Park, Jaehyun Jeon, Jihye Um, et al.
Infection and Chemotherapy (2024) Vol. 56, Iss. 1, pp. 25-25
Open Access | Times Cited: 2
Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection
Irène A. Abela, Magdalena Schwarzmüller, Agnė Ulytė, et al.
mBio (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 2
Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity
Alex Roederer, Yi Cao, Kerri St. Denis, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination
Sharon Walmsley, Majid Nabipoor, Freda Qi, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 564-564
Open Access | Times Cited: 2
Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults
Simon Dedroogh, Sven Schmiedl, Petra A. Thürmann, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 7
Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination
William S. Foster, Jia Le Lee, Nazia Thakur, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 12, pp. 100845-100845
Open Access | Times Cited: 11
Association between sex hormones and anti-S/RBD antibody responses to COVID-19 vaccines in healthcare workers
Simona Anticoli, Maria Dorrucci, Elisabetta Iessi, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 3
Open Access | Times Cited: 6
A third high dose of inactivated COVID-19 vaccine induces higher neutralizing antibodies in humans against the Delta and Omicron variants: a Randomized, Double-Blinded Clinical Trial
Yu Cao, Xiaoli Wang, Siqi Li, et al.
Science China Life Sciences (2022) Vol. 65, Iss. 8, pp. 1677-1679
Open Access | Times Cited: 10
Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults
Prasert Assantachai, Suvimol Niyomnaitham, Wichai Chatthanawaree, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. 7, pp. 868-877
Open Access | Times Cited: 5
Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients
Zhe Zhang, Shipo Wu, Yawei Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Propylene glycol inactivates respiratory viruses and prevents airborne transmission
Christine T. Styles, Jie Zhou, Katie E. Flight, et al.
EMBO Molecular Medicine (2023) Vol. 15, Iss. 12
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top